A dramatic increase in the prevalence of obesity worldwide, reaching epidemic levels, has illustrated the urgent need to better understand the causes, and underlying molecular pathways and develop further therapeutic agents to aid in this challenge. Moreover, obesity represents a major risk factor with a number of associated diseases that affect productivity and quality of life and add to increasing healthcare expenses.
There are number of promising current approaches for obesity management, such as lifestyle modification, pharmacotherapy, and bariatric surgery. Also, the management of obesity has been improved to include natural compounds including probiotics, prebiotics, and synbiotics; synthetic drugs such as liraglutide, dietary interventions such as keto-diet; and intermittent fasting. However, a major concern that remains observed is the limited weight loss in the majority of the patients, particularly in children. Thus, the development and management of obesity still requires attention to overcome the issue and manage the downstream disease risk factors.
Another constant challenge is the emerging and progressive era of hepatic insulin resistance and related obesity. Research has detailed the mechanisms involved in this such as Serine/Threonine phosphorylation of IRS, inflammasome NLRP3, and ferroptosis. However, further exploration is required.
The study of obesity etiology has also progressed to illustrate the maternal role and genetic role in developing obesity in children. Current research has identified the effect of maternal obesity on fetal brain development.
The aim of this Research Topic is to gather original research manuscripts, meta-analyses, and review articles looking at hepatic insulin resistance, obesity and related disorders, e.g. type 2 diabetes, metabolic syndrome, neurodegenerative disorders, non-alcoholic fatty liver disease, hepatocellular carcinoma, and others. The research highlighting the effect of natural compounds, dietary intervention and synthetic drugs will be interesting. Moreover, highlighting molecular mechanisms that deal with positive/negative Serine/Threonine phosphorylation of IRS, inflammasome, and oxidative stress will also be considered. The above-mentioned potential topics are suggestions; other relevant topics will also be considered.
A dramatic increase in the prevalence of obesity worldwide, reaching epidemic levels, has illustrated the urgent need to better understand the causes, and underlying molecular pathways and develop further therapeutic agents to aid in this challenge. Moreover, obesity represents a major risk factor with a number of associated diseases that affect productivity and quality of life and add to increasing healthcare expenses.
There are number of promising current approaches for obesity management, such as lifestyle modification, pharmacotherapy, and bariatric surgery. Also, the management of obesity has been improved to include natural compounds including probiotics, prebiotics, and synbiotics; synthetic drugs such as liraglutide, dietary interventions such as keto-diet; and intermittent fasting. However, a major concern that remains observed is the limited weight loss in the majority of the patients, particularly in children. Thus, the development and management of obesity still requires attention to overcome the issue and manage the downstream disease risk factors.
Another constant challenge is the emerging and progressive era of hepatic insulin resistance and related obesity. Research has detailed the mechanisms involved in this such as Serine/Threonine phosphorylation of IRS, inflammasome NLRP3, and ferroptosis. However, further exploration is required.
The study of obesity etiology has also progressed to illustrate the maternal role and genetic role in developing obesity in children. Current research has identified the effect of maternal obesity on fetal brain development.
The aim of this Research Topic is to gather original research manuscripts, meta-analyses, and review articles looking at hepatic insulin resistance, obesity and related disorders, e.g. type 2 diabetes, metabolic syndrome, neurodegenerative disorders, non-alcoholic fatty liver disease, hepatocellular carcinoma, and others. The research highlighting the effect of natural compounds, dietary intervention and synthetic drugs will be interesting. Moreover, highlighting molecular mechanisms that deal with positive/negative Serine/Threonine phosphorylation of IRS, inflammasome, and oxidative stress will also be considered. The above-mentioned potential topics are suggestions; other relevant topics will also be considered.
